Market Events and Forecast | Ophthalmology | US/EU5 | 2021
In 2019, sales of branded biologics in ophthalmology reached almost $9 billion in the major pharmaceutical markets (United States, EU5, and Japan). Throughout our 2019-2029 forecast period, reference brands Lucentis (ranibizumab) and Eylea (aflibercept) are set to lose patent protection; biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for these two key reference brands and their biosimilars by molecule and region.
Related Market Assessment Reports
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
Report
Atopic Dermatitis / Atopic Eczema – Access & Reimbursement – Access & Reimbursement – Atopic Dermatitis (US)
The treatment landscape for AD in the United States is evolving rapidly. Since 2017, the FDA has approved multiple agents, including systemic and topical JAK inhibitors, nonsteroidal topical…
Report
Painful Diabetic Neuropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Painful Diabetic Neuropathy (US)
Painful diabetic neuropathy (PDN) is characterized by numbness, tingling, and burning, sharp, shooting, or other painful sensations, commonly in the feet, legs, and/or hands. PDN is managed with…
